Schizophrenia - aripiprazole (TA213)
Fast, easy summary view of NICE guidance on 'psychosis and schizophrenia in children and young people'
NICE recommends aripiprazole as a possible treatment for some people aged 15 to 17 years with schizophrenia.
You should be able to have aripiprazole if:
- you cannot take risperidone for medical reasons or
- you have taken risperidone but it has not worked.
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended aripiprazole in these circumstances because it works as well and costs about the same as other alternatives to risperidone available on the NHS, but is less likely to produce the types of side effects that are especially troublesome for people aged 15 to 17 years.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: psychosis and schizophrenia in children and young people
This page was last updated: 18 January 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA213 Aripiprazole ar gyfer sgitsoffrenia mewn pobl ifanc 15 - 17 oed: deall canllawiau NICE
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.